Edap Tms Sa
FOCL Nasdaq Electromedical & Electrotherapeutic Apparatus Financials FY2024–FY2025
Last close · Oct 23, 2026
$4.17
0.5%What Edap Tms Sa does
No business description yet.
- Legal name
- EDAP TMS SA
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 25, 2026
- Accession · CIK
- 0001104659-26-034528
0001041934
Revenue and margins
Edap Tms Sa had $70.5M of revenue in fiscal 2025, up 1.6% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Edap Tms Sa returned — to shareholders in fiscal 2025. The diluted share count rose 0.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably Edap Tms Sa can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $31.0M | $20.5M |
| Debt incl. finance leases | $11.8M | $22.9M |
| Debt / equity | 0.3x | 1.2x |
| Interest coverage | −86.8x | −31.3x |
| Current ratio | 1.8x | 1.5x |
| Quick ratio | 1.4x | 1.3x |
| Total assets | $89.4M | $79.0M |
| Total liabilities | $46.9M | $59.6M |
| Shareholders' equity | $42.5M | $19.4M |
| Net debt (− = net cash) | −$19.2M | $2.4M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | ✕ |
| Current ratio rose | — | ✕ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | ✓ |
| Revenue rose relative to assets | — | ✓ |
| F-score | — / 3 | 3 / 9 |
| Accruals ratio | −6.6% | −15.2% |
| Altman Z'' | −1.90 | −5.40 |
2 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $69.4M | $70.5M |
| Gross profit | $28.7M | $30.0M |
| Research and development | $8.4M | $9.7M |
| Operating income | −$22.2M | −$24.7M |
| Interest expense | $0.3M | $0.8M |
| Pretax income | −$20.3M | −$28.8M |
| Income tax | $0.3M | $0.4M |
| Net income | −$20.6M | −$29.2M |
| Diluted EPS | −$0.55 | −$0.78 |
| Diluted shares | 0.04B | 0.04B |
| Cash flow | ||
| Cash from operations | −$14.7M | −$16.4M |
| Depreciation and amortization | $2.8M | $3.4M |
| Balance sheet | ||
| Cash and short-term investments | $31.0M | $20.5M |
| Total debt | $11.2M | $22.4M |
| Finance lease liabilities | $0.5M | $0.5M |
| Current assets | $72.6M | $57.2M |
| Current liabilities | $39.3M | $37.1M |
| Inventory | $19.2M | $7.8M |
| Property and equipment, net | $7.6M | $9.9M |
| Goodwill | $2.5M | $0.8M |
| Intangible assets | $1.1M | $1.8M |
| Total assets | $89.4M | $79.0M |
| Total liabilities | $46.9M | $59.6M |
| Shareholders' equity | $42.5M | $19.4M |
| Margins | ||
| Gross margin | 41.4% | 42.5% |
| Operating margin | −32.0% | −35.0% |
| EBITDA margin | −28.0% | −30.2% |
| Net margin | −29.7% | −41.5% |
| Returns | ||
| Return on capital | −77.3% | −91.5% |
| Return on capital employed | −44.3% | −59.0% |
| Return on equity | −48.5% | −94.5% |
| Return on assets | −23.0% | −34.7% |
| Return on tangible equity | −53.0% | −173.4% |
| Growth | ||
| Revenue growth | — | 1.6% |
| Share count change | — | 0.4% |
| Financial health | ||
| Debt / equity | 0.3x | 1.2x |
| Interest coverage | −86.8x | −31.3x |
| Current ratio | 1.8x | 1.5x |
| Quick ratio | 1.4x | 1.3x |
| Quality scores | ||
| Piotroski F-score | — | 3.0 |
| Altman Z'' | −1.9 | −5.4 |
| Accruals ratio | −6.6% | −15.2% |
Source: SEC EDGAR XBRL filings (CIK 0001041934). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.